Bhavana Brahmananda Bhat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bhavana Brahmananda Bhat has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Sreedhar Dharmagadda
Manipal Academy of Higher Education
2 shared publications Anusha
1 shared publication- Aravinda Pai
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India
1 shared publication B Venkatesh Kamath
1 shared publication- Chandrashekar Kodangala Subraya
Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, MAHE, Manipal, 576104, Karnataka, India
1 shared publication Dharmagadda Sreedhar
Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka, India
1 shared publication
Latest Publications
- 3 August 2026
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 26, 1-20
Epigenetic Modifiers and Synthetic Lethality in Cancer Therapy: Emerging Targets Beyond Traditional Approaches
As the field of anticancer drug development is constantly changing, combining synthetic lethality with epigenetic modifiers opens up new possibilities for targets that fall outside the traditional drug target range. Enzymes involved in DNA methylation and histone modification are examples of epigenetic modifiers that promote gene expression without altering the DNA sequence of the gene. These mechanisms play a key role in carcinogenesis when they are altered, as they downregulate tumor suppressor genes and overexpress oncogenic pathways. Synthetic lethality is a phenomenon in which simultaneous mutations or perturbations of two genes result in cell death, but alterations to one gene alone do not cause cell death. It was first observed in genetic research conducted on model organisms, such as fruit flies and fungi. The most well-known example of this idea from the perspective of cancer treatment is PARP inhibitors, which are effective in tumors with BRCA1/2 mutations, where further failure of DNA repair results in cell sensitization. Building on the concept of synthetic lethality, current research focuses on exploiting epigenetic flaws that are common in cancer cells. For example, when chromatin remodelers or methyltransferases cease to function, malignant cells undergo genetic rewiring, rendering them vulnerable to treatment. Recent research has produced some striking examples of synthetic-lethal drug interactions and biomarkers used in metagenomics for personalized medicine by targeting the secondary pathways used by cancer cells as a result of primary loss-of-function mutations, which selectively kill cancer cells while sparing healthy cells. The discovery of actionable epigenetic dependencies and overcoming tumor heterogeneity remain the largest challenges in translating these fascinating scientific discoveries to the clinic. The convergence of epigenetic modulators with synthetic-lethality-based therapeutic architectures is poised to define a transformative paradigm in precision oncology. By orchestrating multilayered perturbations across chromatin-regulatory networks, DNA damage–response pathways, and context-specific vulnerability nodes, this integrative strategy surpasses the limitations of conventional target-centric pharmacology and enables mechanistically rational, synergistic antitumor interventions.
- 3 August 2026
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 26, 1-20
Epigenetic Modifiers and Synthetic Lethality in Cancer Therapy: Emerging Targets Beyond Traditional Approaches
As the field of anticancer drug development is constantly changing, combining synthetic lethality with epigenetic modifiers opens up new possibilities for targets that fall outside the traditional drug target range. Enzymes involved in DNA methylation and histone modification are examples of epigenetic modifiers that promote gene expression without altering the DNA sequence of the gene. These mechanisms play a key role in carcinogenesis when they are altered, as they downregulate tumor suppressor genes and overexpress oncogenic pathways. Synthetic lethality is a phenomenon in which simultaneous mutations or perturbations of two genes result in cell death, but alterations to one gene alone do not cause cell death. It was first observed in genetic research conducted on model organisms, such as fruit flies and fungi. The most well-known example of this idea from the perspective of cancer treatment is PARP inhibitors, which are effective in tumors with BRCA1/2 mutations, where further failure of DNA repair results in cell sensitization. Building on the concept of synthetic lethality, current research focuses on exploiting epigenetic flaws that are common in cancer cells. For example, when chromatin remodelers or methyltransferases cease to function, malignant cells undergo genetic rewiring, rendering them vulnerable to treatment. Recent research has produced some striking examples of synthetic-lethal drug interactions and biomarkers used in metagenomics for personalized medicine by targeting the secondary pathways used by cancer cells as a result of primary loss-of-function mutations, which selectively kill cancer cells while sparing healthy cells. The discovery of actionable epigenetic dependencies and overcoming tumor heterogeneity remain the largest challenges in translating these fascinating scientific discoveries to the clinic. The convergence of epigenetic modulators with synthetic-lethality-based therapeutic architectures is poised to define a transformative paradigm in precision oncology. By orchestrating multilayered perturbations across chromatin-regulatory networks, DNA damage–response pathways, and context-specific vulnerability nodes, this integrative strategy surpasses the limitations of conventional target-centric pharmacology and enables mechanistically rational, synergistic antitumor interventions.
- 11 December 2019
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 16 (4) , 368-371
Herbal Products Regulations in a Few Countries-A Brief Overview
Herbal medicines have been used by mankind from time immemorial. Moreover, many modern medicines are originated from plant sources. In earlier days, patients were dependent on herbs for treatment and well-being. However, due to the advent of the industrial revolution and modern science, the scenario of treating diseases has changed over a period of time. Majority of patients started preferring allopathy medicines due to their several advantages over herbal medicines. However, due to long term treatment by allopathic medicines for chronic diseases led to side effects, patients are now drifting back to the traditional medicines. Herbal medicines have their own drawbacks, viz., lack of safety and efficacy data, standardization difficulties, not well established legislative controls and a few issues with adverse drug reactions. Drug regulations per se were always the prime focus and they are said to be dynamic. There are a few differences in regulations of herbal drugs among various countries. Regulatory authorities of countries are working to evolve the regulations to govern herbal medicines more effectively. A brief overview of the regulations related to a few developing and developed countries have been dealt here.
- 11 December 2019
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 16 (4) , 368-371
Herbal Products Regulations in a Few Countries-A Brief Overview
Herbal medicines have been used by mankind from time immemorial. Moreover, many modern medicines are originated from plant sources. In earlier days, patients were dependent on herbs for treatment and well-being. However, due to the advent of the industrial revolution and modern science, the scenario of treating diseases has changed over a period of time. Majority of patients started preferring allopathy medicines due to their several advantages over herbal medicines. However, due to long term treatment by allopathic medicines for chronic diseases led to side effects, patients are now drifting back to the traditional medicines. Herbal medicines have their own drawbacks, viz., lack of safety and efficacy data, standardization difficulties, not well established legislative controls and a few issues with adverse drug reactions. Drug regulations per se were always the prime focus and they are said to be dynamic. There are a few differences in regulations of herbal drugs among various countries. Regulatory authorities of countries are working to evolve the regulations to govern herbal medicines more effectively. A brief overview of the regulations related to a few developing and developed countries have been dealt here.
- Open Access
- 13 February 2019
- Published by African Journals Online (AJOL) in Tropical Journal of Pharmaceutical Research
- Vol. 18 (1) , 117-121
Assessment of knowledge and attitude of patients on herbal medicine use in Udupi region, Karnataka, India
Assessment of knowledge and attitude of patients on herbal medicine use in Udupi region, Karnataka, India
- 13 February 2019
- Published by African Journals Online (AJOL) in Tropical Journal of Pharmaceutical Research
- Vol. 18 (1) , 117-121
Open AccessAssessment of knowledge and attitude of patients on herbal medicine use in Udupi region, Karnataka, India
Assessment of knowledge and attitude of patients on herbal medicine use in Udupi region, Karnataka, India
- 1 January 2019
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 12 (12) , 5959
Medical Device Industry in India: Past to Present
- 1 January 2019
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 12 (12) , 5959
Medical Device Industry in India: Past to Present
- 1 January 2018
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 11 (1) , 117
Knowledge and attitude of Ayurvedic Physicians towards Adverse drug reactions and reporting methods in Udupi region
- 1 January 2018
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 11 (1) , 117
Knowledge and attitude of Ayurvedic Physicians towards Adverse drug reactions and reporting methods in Udupi region